CYP3A5 genetic polymorphism in HIV-patients

Poster presented at the From Basic Sciences to Clinical Research - First International Congress of CiiEM. Egas Moniz, Caparica, Portugal, 27-28 November 2015

"A number of relevant polymorphisms are known for affecting the most common prescribed ARVs (antiretroviral), inducing drug toxicity, risk of virologic failure and may explain the interpatient variability for drug absorption pathways. CYP3A5 is an isoform of Cytochromes P4503A family, estimated to participate in the metabolism of 40 to 60% of all clinically administered drugs, namely atazanavir (1). The aim of this study was to characterize the CYP3A5 polymorphisms of HIV infected patients, from Santa Maria Hospital, Lisbon, Portugal."